A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI – GINECO study
Author:
Florence Joly,Michel Fabbro,Philippe Follana,Justine Lequesne,Jacques Medioni,Anne Lesoin,Jean-Sébastien Frenel,Sophie Abadie-Lacourtoisie,Anne Floquet,Laurence Gladieff,Benoît You,Céline Gavoille,Elsa Kalbacher,Mélanie Briand et al.
Publication:
Gynecologic Oncology
© 2022 Elsevier Inc. All rights reserved.